FINWIRES · TerminalLIVE
FINWIRES

New Zealand Shares Flat; KMD Brands Secures NZ$11 Million in Retail Entitlement Offer Completion

-- New Zealand shares ended flat on Tuesday despite a broad-based rise in Asian shares as investors showed optimism around the US-Iran peace talks.

The S&P/NZX 50 Index was little changed to close at 12,932.33.

Iran is considering attending peace negotiations with the US in Pakistan, while Islamabad attempts to end a US blockade on Iranian ports, which is seen as a key obstacle to Tehran's participation, before a two-week ceasefire expires, Reuters said in a separate report, citing a senior Iranian official.

Meanwhile, New Zealand Prime Minister Christopher Luxon said on Tuesday he had the backing of National Party lawmakers after holding a leadership confidence vote, following days of speculation that some within the party were pushing to replace him, according to a Tuesday Reuters report.

In domestic news, Business confidence in New Zealand declined in the March quarter, as the US-Israel war with Iran fanned fuel prices and caused supply-chain disruptions amid worsening uncertainty around the Strait of Hormuz, the New Zealand Institute of Economic Research (NZIER) said.

Meanwhile, New Zealand's annual consumer inflation increased by 3.1% in the March quarter, unchanged from the 3.1% increase in the 12 months to the December 2025 quarter, data from Stats NZ showed.

Also, New Zealand consumer prices rose 0.9% in the March quarter, with the annual inflation rate remaining unchanged at 3.1%, resulting in this quarter's inflation going above the previously anticipated 0.7% rise, Westpac said in a report.

In corporate news, KMD Brands (ASX:KMD, NZE:KMD) has completed the retail component of its fully underwritten 1-for-0.73 accelerated renounceable entitlement offer, with eligible shareholders subscribing for around 182.6 million new shares at NZ$0.06 each, raising about NZ$11 million as part of a total NZ$58.5 million capital raising.

Black Pearl Group (ASX:BPG, NZE:BPG) reported fiscal fourth quarter annual recurring revenue (ARR) of NZ$26.8 million, up 114% year on year.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524